Citation

Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Psychopharmacology 2005; 181(2): 237-243.

Affiliation

Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians, Surgeons of Columbia University, NY 10032, USA. clh42@columbia.edu

Copyright

(Copyright © 2005, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s00213-005-2234-2

PMID

15830233

Abstract

RATIONALE: Oral Delta-9-tetrahydrocannabinol (Delta(9)-THC; Marinol) is medically available for the treatment of nausea associated with cancer chemotherapy and for wasting syndromes related to HIV/AIDS. Little is known about its reinforcing effects. OBJECTIVE: This study was conducted to characterize the reinforcing effects of oral Delta(9)-THC in experienced marijuana smokers under controlled laboratory conditions. METHODS: Ten healthy male marijuana users completed this 17-day residential study. On days 2, 6, 10, and 14, at 0900 h, participants received a "sample" oral dose of Delta(9)-THC (0, 10, 20 mg) and an alternative reinforcer, a 2 US dollars voucher (redeemable for cash at study's end). Over the next 3 days, they had 11 opportunities to self-administer either the sampled dose of Delta(9)-THC or to receive a 2 US dollars voucher. RESULTS: Participants chose active Delta(9)-THC (10 and 20 mg) more often than placebo (

Language: en